Literature DB >> 21621695

The prevention and treatment of intestinal failure-associated liver disease in neonates and children.

Deepika Nehra1, Erica M Fallon, Mark Puder.   

Abstract

Intestinal Failure Associated Liver Disease (IFALD) is a common and potentially life-threatening problem for pediatric patients receiving long-term parenteral nutrition (PN). Risk factors for IFALD include premature birth, low birth weight, long-term PN, intestinal stasis and sepsis. Preventative strategies are the cornerstone of improving outcomes in IFALD and include enteral feeding, weaning of PN, reduced dose lipid emulsions and the early recognition and treatment of sepsis. Recent work also demonstrates the efficacy of fish-oil based lipid emulsions in the prevention and treatment of IFALD. Transplantation is an option for end-stage liver disease but is associated with significant morbidity and mortality. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21621695     DOI: 10.1016/j.suc.2011.02.003

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  12 in total

1.  Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.

Authors:  Adam S Brinkman; Sangita G Murali; Stacy Hitt; Patrick M Solverson; Jens J Holst; Denise M Ney
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-28       Impact factor: 4.052

2.  Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs.

Authors:  Barbara Stoll; Patrycja Jolanta Puiman; Liwei Cui; Xiaoyan Chang; Nancy Marie Benight; Caroline Bauchart-Thevret; Bolette Hartmann; Jens Juul Holst; Douglas Guy Burrin
Journal:  JPEN J Parenter Enteral Nutr       Date:  2012-05-01       Impact factor: 4.016

3.  Early detection of liver fibrosis with serum Mac-2 binding protein glycosylation-modified isomer (M2BPGi) during follow-up intestinal failure patients without intestinal failure-associated liver disease (IFALD).

Authors:  Takehisa Ueno; Koki Takase; Koichi Deguchi; Kazunori Masahata; Motonari Nomura; Miho Watanabe; Masafumi Kamiyama; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2022-09-20       Impact factor: 2.003

4.  Parenteral lipid emulsions in guinea pigs differentially influence plasma and tissue levels of fatty acids, squalene, cholesterol, and phytosterols.

Authors:  Kevin Harvey; Zhidong Xu; Candace Walker; Thomas Pavlina; Sheila McGrath; Gary Zaloga; Rafat Siddiqui
Journal:  Lipids       Date:  2014-07-06       Impact factor: 1.880

5.  Risks and benefits of prophylactic cyclic parenteral nutrition in surgical neonates.

Authors:  T Hang Nghiem-Rao; Laura D Cassidy; Elizabeth M Polzin; Casey M Calkins; Marjorie J Arca; Praveen S Goday
Journal:  Nutr Clin Pract       Date:  2013-10-09       Impact factor: 3.080

6.  Aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure.

Authors:  Juan J Díaz; Kathleen M Gura; Juliamna Roda; Antonio R Perez-Atayde; Christopher Duggan; Tom Jaksic; Clifford W Lo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-09       Impact factor: 2.839

7.  Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children.

Authors:  Prathima Nandivada; Meredith A Baker; Paul D Mitchell; Alison A O'Loughlin; Alexis K Potemkin; Lorenzo Anez-Bustillos; Sarah J Carlson; Duy T Dao; Gillian L Fell; Kathleen M Gura; Mark Puder
Journal:  Am J Clin Nutr       Date:  2016-08-10       Impact factor: 7.045

Review 8.  The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD).

Authors:  Melissa I Chang; Mark Puder; Kathleen M Gura
Journal:  Nutrients       Date:  2012-11-27       Impact factor: 5.717

9.  Glutamine-supplemented parenteral nutrition and probiotics in four adult autoimmune enteropathy patients.

Authors:  Ren Ying Xu; Yan Ping Wan; Yi Quan Zhou; Li Ping Lu; Zhi Qi Chen; Ying Jie Wu; Wei Cai
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519

10.  Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs.

Authors:  Kristin A Sauter; Lindsey A Waddell; Zofia M Lisowski; Rachel Young; Lucas Lefevre; Gemma M Davis; Sara M Clohisey; Mary McCulloch; Elizabeth Magowan; Neil A Mabbott; Kim M Summers; David A Hume
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-21       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.